Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000950170-22-006985
Filing Date
2022-05-03
Accepted
2022-05-03 10:33:49
Documents
2

Document Format Files

Seq Description Document Type Size
1 DEFA14A ikt-naa_card-2022.htm DEFA14A 12745
2 GRAPHIC img1511599_0.jpg GRAPHIC 233557
  Complete submission text file 0000950170-22-006985.txt   335552
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-39676 | Film No.: 22885035
SIC: 2836 Biological Products, (No Diagnostic Substances)